Journal of Tuberculosis and Lung Disease ›› 2023, Vol. 4 ›› Issue (5): 425-431.doi: 10.19983/j.issn.2096-8493.20230090
• Review Articles • Previous Articles Next Articles
Feng Yi, Chang Qing, Li Feng()
Received:
2023-08-16
Online:
2023-10-20
Published:
2023-10-16
Contact:
Li Feng, Email: Supported by:
CLC Number:
Feng Yi, Chang Qing, Li Feng. Research progress of combined pulmonary fibrosis and emphysema[J]. Journal of Tuberculosis and Lung Disease , 2023, 4(5): 425-431. doi: 10.19983/j.issn.2096-8493.20230090
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.jtbld.cn/EN/10.19983/j.issn.2096-8493.20230090
[1] |
Papaioannou AI, Kostikas K, Manali ED, et al. Combined pulmonary fibrosis and emphysema: the many aspects of a cohabitation contract. Respir Med, 2016, 117:14-26. doi:10.1016/j.rmed.2016.05.005.
pmid: 27492509 |
[2] |
Jankowich MD, Rounds SIS. Combined pulmonary fibrosis and emphysema syndrome: a review. Chest, 2012, 141(1):222-231. doi:10.1378/chest.11-1062.
pmid: 22215830 |
[3] |
Cottin V, Nunes H, Brillet PY, et al. Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J, 2005, 26(4):586-593. doi:10.1183/09031936.05.00021005.
pmid: 16204587 |
[4] | Cottin V. Combined pulmonary fibrosis and emphysema: bad and ugly all the same? Eur Respir J, 2017, 50(1):1700846. doi:10.1183/13993003.00846-2017. |
[5] | Çiftci F, Gülpınar B, Atasoy Ç, et al. Combined pulmonary fibrosis and emphysema: How does cohabitation affect respiratory functions? Adv Med Sci, 2019, 64(2):285-291. doi:10.1016/j.advms.2019.03.005. |
[6] |
Fujimoto K, Kitaguchi Y, Kubo K, et al. Clinical analysis of chronic obstructive pulmonary disease phenotypes classified using high-resolution computed tomography. Respirology, 2006, 11(6):731-740. doi:10.1111/j.1440-1843.2006.00930.x.
pmid: 17052301 |
[7] | Sangani R, Ghio A, Culp S, et al. Combined Pulmonary Fibrosis Emphysema: Role of Cigarette Smoking and Pulmonary Hypertension in a Rural Cohort. Int J Chron Obstruct Pulmon Dis, 2021, 16:1873-1885. doi:10.2147/COPD.S307192. |
[8] |
Chae KJ, Jin GY, Han YM, et al. Prevalence and progression of combined pulmonary fibrosis and emphysema in asymptomatic smokers: A case-control study. Eur Radiol, 2015, 25(8):2326-2334. doi:10.1007/s00330-015-3617-3.
pmid: 25680720 |
[9] | 许飞, 陈群慧, 张海, 等. 肺纤维化合并肺气肿在社区肺癌高危人群筛查项目中的流行病学研究. 中国呼吸与危重监护杂志, 2021, 20(10): 709-714. doi:10.7507/1671-6205.202105049. |
[10] |
Andersson M, Blanc PD, Torén K, et al. Smoking, occupational exposures, and idiopathic pulmonary fibrosis among Swedish construction workers. Am J Ind Med, 2021, 64(4):251-257. doi:10.1002/ajim.23231.
pmid: 33547652 |
[11] |
Hirano ACG, Targueta EP, Ferraz de Campos FP, et al. Severe pulmonary hypertension due to combined pulmonary fibrosis and emphysema: another cause of death among smokers. Autops Case Rep, 2017, 7(2):15-26. doi:10.4322/acr.2017.022.
pmid: 28740835 |
[12] | Jacob J, Bartholmai BJ, Rajagopalan S, et al. Functional and prognostic effects when emphysema complicates idiopathic pulmonary fibrosis. Eur Respir J, 2017, 50(1):1700379. doi:10.1183/13993003.00379-2017. |
[13] | Chae KJ, Jin GY, Jung HN, et al. Differentiating Smoking-Related Interstitial Fibrosis (SRIF) from Usual Interstitial Pneumonia (UIP) with Emphysema Using CT Features Based on Pathologically Proven Cases. PLoS One, 2016, 11(9):e0162231. doi:10.1371/journal.pone.0162231. |
[14] | Liu Q, Gao Y, Ci X. Role of Nrf2 and Its Activators in Respiratory Diseases. Oxid Med Cell Longev, 2019, 2019:7090534. doi:10.1155/2019/7090534. |
[15] | Antoniou KM, Margaritopoulos GA, Goh NS, et al. Combined Pulmonary Fibrosis and Emphysema in Scleroderma-Related Lung Disease Has a Major Confounding Effect on Lung Physiology and Screening for Pulmonary Hypertension. Arthritis Rheumatol, 2016, 68(4):1004-1012. doi:10.1002/art.39528. |
[16] |
Jacob J, Song JW, Yoon HY, et al. Prevalence and Effects of Emphysema in Never-Smokers with Rheumatoid Arthritis Interstitial Lung Disease. EBioMedicine, 2018, 28:303-310. doi:10.1016/j.ebiom.2018.01.038.
pmid: 29422289 |
[17] | Ariani A, Silva M, Bravi E, et al. Overall mortality in combined pulmonary fibrosis and emphysema related to systemic sclerosis. RMD Open, 2019, 5(1):e000820. doi:10.1136/rmdopen-2018-000820. |
[18] |
Tzouvelekis A, Zacharis G, Oikonomou A, et al. Increased incidence of autoimmune markers in patients with combined pulmonary fibrosis and emphysema. BMC Pulm Med, 2013, 13:31. doi:10.1186/1471-2466-13-31.
pmid: 23697753 |
[19] |
Bédard Méthot D, Leblanc É, Lacasse Y. Meta-analysis of Gastroesophageal Reflux Disease and Idiopathic Pulmonary Fibrosis. Chest, 2019, 155(1):33-43. doi:10.1016/j.chest.2018.07.038.
pmid: 30120950 |
[20] | Hage R, Gautschi F, Steinack C, et al. Combined Pulmonary Fibrosis and Emphysema (CPFE) Clinical Features and Management. Int J Chron Obstruct Pulmon Dis, 2021, 16:167-177. doi:10.2147/COPD.S286360. |
[21] |
Cottin V, Reix P, Khouatra C, et al. Combined pulmonary fibrosis and emphysema syndrome associated with familial SFTPC mutation. Thorax, 2011, 66(10):918-919. doi:10.1136/thx.2010.151407.
pmid: 21248320 |
[22] | Ota C, Kimura M, Kure S. ABCA3 mutations led to pulmonary fibrosis and emphysema with pulmonary hypertension in an 8-year-old girl. Pediatr Pulmonol, 2016, 51(6):E21-3. doi:10.1002/ppul.23379. |
[23] | Holm AT, Wulf-Johansson H, Hvidsten S, et al. Characterization of spontaneous air space enlargement in mice lacking microfibrillar-associated protein 4. Am J Physiol Lung Cell Mol Physiol, 2015, 308(11):L1114-24. doi:10.1152/ajplung.00351.2014. |
[24] |
Molina-Molina M, Borie R. Clinical implications of telomere dysfunction in lung fibrosis. Curr Opin Pulm Med, 2018, 24(5):440-444. doi:10.1097/MCP.0000000000000506.
pmid: 30067250 |
[25] |
Hoffman TW, Borie R, et al. Pulmonary phenotypes associated with genetic variation in telomere-related genes. Curr Opin Pulm Med, 2018, 24(3):269-280. doi:10.1097/MCP.0000000000000475.
pmid: 29474209 |
[26] |
Cottin V, Le Pavec J, Prévot G, et al. Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome. Eur Respir J. 2010, 35(1):105-111. doi:10.1183/09031936.00038709.
pmid: 19643948 |
[27] |
Zhang L, Zhang C, Dong F, et al. Combined pulmonary fibrosis and emphysema: a retrospective analysis of clinical characteristics, treatment and prognosis. BMC Pulm Med, 2016, 16(1):137. doi:10.1186/s12890-016-0300-7.
pmid: 27809901 |
[28] | Yoon HY, Kim TH, Seo JB, et al. Effects of emphysema on physiological and prognostic characteristics of lung function in idiopathic pulmonary fibrosis. Respirology, 2019, 24(1):55-62. doi:10.1111/resp.133878. Epub 201 Aug 23. |
[29] |
Wong AW, Liang J, Cottin V, et al. Diagnostic Features in Combined Pulmonary Fibrosis and Emphysema: A Systematic Review. Ann Am Thorac Soc, 2020, 17(10):1333-1336. doi:10.1513/AnnalsATS.202002-122RL.
pmid: 32610025 |
[30] |
Lin H, Jiang S. Combined pulmonary fibrosis and emphysema (CPFE): an entity different from emphysema or pulmonary fibrosis alone. J Thorac Dis, 2015, 7(4):767-779. doi:10.3978/j.issn.2072-1439.2015.04.17.
pmid: 25973246 |
[31] |
Cottin V, Cordier JF. Combined pulmonary fibrosis and emphysema in connective tissue disease. Curr Opin Pulm Med, 2012, 18(5):418-427. doi:10.1097/MCP.0b013e328356803b.
pmid: 22781207 |
[32] |
Brillet PY, Cottin V, Letoumelin P, et al. Syndrome emphysème des sommets et fibrose pulmonaire des bases combinés (syndrome emphysème/fibrose): aspects tomoden-sitométriques et fonctionnels [Combined apical emphysema and basal fibrosis syndrome (emphysema/fibrosis syndrome): CT imaging features and pulmonary function tests. J Radiol, 2009, 90(1 Pt 1):43-51. French. doi:10.1016/s0221-0363(09)70077-0.
pmid: 19182713 |
[33] |
Kinoshita Y, Watanabe K, Ishii H, et al. Distribution of emphysema and fibrosis in idiopathic pulmonary fibrosis with coexisting emphysema. Histopathology, 2019, 74(7):1103-1108. doi:10.1111/his.13831.
pmid: 30715748 |
[34] |
Ryerson CJ, Hartman T, Elicker BM, et al. Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis. Chest, 2013, 144(1):234-240. doi:10.1378/chest.12-2403.
pmid: 23370641 |
[35] | Robledo GC, Hernández MYJ, Lucas SAG, et al. Combined Pulmonary Fibrosis and Emphysema With Pulmonary Hypertension: Cases Report. Curr Probl Cardiol, 2022, 47(4):100856. doi:10.1016/j.cpcardiol.2021.100856. |
[36] |
Fleming H, Clifford SM, Haughey A, et al. Differentiating combined pulmonary fibrosis and emphysema from pure emphysema: utility of late gadolinium-enhanced MRI. Eur Radiol Exp, 2020, 4(1):61. doi:10.1186/s41747-020-00187-w.
pmid: 33141269 |
[37] | Cottin V, Selman M, Inoue Y, et al. Syndrome of Combined Pulmonary Fibrosis and Emphysema: An Official ATS/ERS/JRS/ALAT Research Statement. Am J Respir Crit Care Med, 2022, 206(4):e7-e41. doi:10.1164/rccm.202206-1041ST. |
[38] |
Caminati A, Cassandro R, Harari S. Pulmonary hypertension in chronic interstitial lung diseases. Eur Respir Rev, 2013, 22(129):292-301. doi:10.1183/09059180.00002713.
pmid: 23997057 |
[39] | Seeger W, Adir Y, Barberà JA, et al. Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol, 2013, 62(25 Suppl):D109-16. doi:10.1016/j.jacc.2013.10.036. |
[40] | Malli F, Papakosta D, Antoniou K, et al. Combined pulmonary fibrosis and emphysema characteristics in a Greek cohort. ERJ Open Res, 2019, 5(1):00014-2018. doi:10.1183/23120541.00014-2018. |
[41] | Sugino K, Ota H, Fukasawa Y, et al. Pathological characteri-stics in idiopathic nonspecific interstitial pneumonia with emphysema and pulmonary hypertension. Respirol Case Rep, 2013, 1(2):39-42. doi:10.1002/rcr2.18. |
[42] |
Jacob J, Bartholmai BJ, Rajagopalan S, et al. Likelihood of pulmonary hypertension in patients with idiopathic pulmonary fibrosis and emphysema. Respirology, 2018, 23(6):593-599. doi:10.1111/resp.13231.
pmid: 29237236 |
[43] |
Inomata M, Ikushima S, Awano N, et al. An autopsy study of combined pulmonary fibrosis and emphysema: correlations among clinical, radiological, and pathological features. BMC Pulm Med, 2014, 14:104. doi:10.1186/1471-2466-14-104.
pmid: 24972672 |
[44] | Nasim F, Moua T. Lung cancer in combined pulmonary fibrosis and emphysema: a large retrospective cohort analysis. ERJ Open Res, 2020, 6(4):00521-2020. doi:10.1183/23120541.00521-2020. |
[45] |
Girard N, Marchand-Adam S, Naccache JM, et al. Lung cancer in combined pulmonary fibrosis and emphysema: a series of 47 Western patients. J Thorac Oncol, 2014, 9(8):1162-1170. doi:10.1097/JTO.0000000000000209.
pmid: 25157769 |
[46] |
Yoo H, Jeong BH, Chung MJ, et al. Risk factors and clinical characteristics of lung cancer in idiopathic pulmonary fibrosis: a retrospective cohort study. BMC Pulm Med, 2019, 19(1):149. doi:10.1186/s12890-019-0905-8.
pmid: 31412851 |
[47] | Koo HJ, Do KH, Lee JB, et al. Lung Cancer in Combined Pulmonary Fibrosis and Emphysema: A Systematic Review and Meta-Analysis. PLoS One, 2016, 11(9):e0161437. doi:10.1371/journal.pone.0161437. |
[48] |
Kitaguchi Y, Fujimoto K, Hanaoka M, et al. Clinical characteristics of combined pulmonary fibrosis and emphysema. Respirology, 2010, 15(2):265-271. doi:10.1111/j.1440-1843.2009.01676.x. Epub 2009 Dec 27.
pmid: 20051048 |
[49] | Moon SW, Park MS, Kim YS, Jet al. Combined pulmonary fibrosis and emphysema and idiopathic pulmonary fibrosis in non-small cell lung cancer: impact on survival and acute exacer-bation. BMC Pulm Med, 2019, 19(1):177. doi:10.1186/s12890-019-0951-2. |
[50] | Oh JY, Lee YS, Min KH, et al. Presence of lung cancer and high gender, age, and physiology score as predictors of acute exacerbation in combined pulmonary fibrosis and emphysema: A retrospective study. Medicine (Baltimore), 2018, 97(31):e11683. doi:10.1097/MD.0000000000011683. |
[51] |
Dong F, Zhang Y, Chi F, et al. Clinical efficacy and safety of ICS/LABA in patients with combined idiopathic pulmonary fibrosis and emphysema. Int J Clin Exp Med, 2015, 8(6):8617-25.
pmid: 26309513 |
[52] | Li C, Wang Y, Liu Q, et al. Clinical, radiologic, and physiologic features of idiopathic pulmonary fibrosis (IPF) with and without emphysema. Expert Rev Respir Med, 2022, 16(7):813-821. doi:10.1080/17476348.2022.2093717. |
[53] | Tomioka H, Mamesaya N, Yamashita S, et al. Combined pulmonary fibrosis and emphysema: effect of pulmonary rehabilitation in comparison with chronic obstructive pulmonary disease. BMJ Open Respir Res, 2016, 3(1):e000099. doi:10.1136/bmjresp-2015-000099. |
[54] |
Takahashi T, Terada Y, Pasque MK, et al. Clinical Features and Outcomes of Combined Pulmonary Fibrosis and Emphysema After Lung Transplantation. Chest, 2021, 160(5):1743-1750. doi:10.1016/j.chest.2021.06.036.
pmid: 34186034 |
[55] | Kishaba T, Shimaoka Y, Fukuyama H, et al. A cohort study of mortality predictors and characteristics of patients with combined pulmonary fibrosis and emphysema. BMJ Open, 2012, 2(3):e000988. doi:10.1136/bmjopen-2012-000988. |
[56] |
Mejía M, Carrillo G, Rojas-Serrano J, et al. Idiopathic pulmonary fibrosis and emphysema: decreased survival associated with severe pulmonary arterial hypertension. Chest, 2009, 136(1):10-15. doi:10.1378/chest.08-2306.
pmid: 19225068 |
[57] |
Kohashi Y, Arai T, Sugimoto C, et al. Clinical Impact of Emphysema Evaluated by High-Resolution Computed Tomography on Idiopathic Pulmonary Fibrosis Diagnosed by Surgical Lung Biopsy. Respiration, 2016, 92(4):220-228. doi:10.1159/000448118.
pmid: 27576553 |
[58] | Jiang CG, Fu Q, Zheng CM. Prognosis of combined pulmonary fibrosis and emphysema: comparison with idiopathic pulmonary fibrosis alone. Ther Adv Respir Dis, 2019, 13:1753466619888119. doi:10.1177/1753466619888119. |
[59] |
Kurashima K, Takayanagi N, Tsuchiya N, et al. The effect of emphysema on lung function and survival in patients with idiopathic pulmonary fibrosis. Respirology, 2010, 15(5):843-848. doi:10.1111/j.1440-1843.2010.01778.x.
pmid: 20546187 |
[60] |
Zeba F, Yanning W, Melek J, et al. Prognostic Significance of Pulmonary Artery to Aorta Ratio and Other CT Markers in Pulmonary Fibrosis With and Without Emphysema. Lung, 2021, 199(6):677-680. doi:10.1007/s00408-021-00490-2.
pmid: 34741227 |
[61] |
Liu Q, Sun D, Wang Y, et al. Use of machine learning models to predict prognosis of combined pulmonary fibrosis and emphysema in a Chinese population. BMC Pulm Med, 2022, 22(1):327. doi:10.1186/s12890-022-02124-6.
pmid: 36038872 |
[1] | Yang Shuqi, Li Feng. Advances in PD1/PD-L1 inhibitors in tuberculosis research [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(1): 94-101. |
[2] | Yang Yarui, Guo Xujun, Wei Wei, He Juan, Li Shengbin, Zhong Tao, Gao Wanling, Liu Shoujiang, Liu Shengyuan. Awareness and factors associated with chronic obstructive pulmonary disease among permanent residents aged ≥40 years old in Nanshan District, Shenzhen [J]. Journal of Tuberculosis and Lung Disease, 2024, 5(6): 517-525. |
[3] | Fan Weifang, Huang Jinpeng, Yao Liwei. Advances in pulmonary rehabilitation nursing for patients with post-tuberculosis lung Disease [J]. Journal of Tuberculosis and Lung Disease, 2024, 5(6): 560-566. |
[4] | Zhu Yixing, Chang De. Current status and prospects of management of chronic respiratory diseases [J]. Journal of Tuberculosis and Lung Disease, 2024, 5(6): 567-572. |
[5] | Meng Ting, Chen Jingfang, Deng Guofang, Lin Yi, Ruan Shujin, Liu Linlin, Li Mengjun. Research progress on mental vulnerability and anxiety-depression status in tuberculosis patients [J]. Journal of Tuberculosis and Lung Disease, 2024, 5(6): 583-589. |
[6] | Yuan Lirong, Yang Qinglong, Li Yuling, Li Lin, Deng Shasha, Li Shuhua. Effect of computerized cognitive behavioral therapy in the management of symptom cluster in patients with chronic obstructive pulmonary disease: a randomized controlled trial [J]. Journal of Tuberculosis and Lung Disease, 2024, 5(5): 476-483. |
[7] | Zhao Fei, Zhan Lu. Research progress on the regulation of TLR4 signaling pathway by miR-451a in the pathogenesis of tuberculosis [J]. Journal of Tuberculosis and Lung Disease, 2024, 5(5): 484-488. |
[8] | He Fanyi, Lu Nihong, Du Yingrong. Research progress on the interaction between tuberculosis and COVID-19 [J]. Journal of Tuberculosis and Lung Disease, 2024, 5(4): 345-351. |
[9] | Zhao Jun, Yang Hongyu, Kang Xiong. Research progress on influencing factors and intervention strategies of stigma in patients with pulmonary tuberculosis [J]. Journal of Tuberculosis and Lung Disease, 2024, 5(4): 364-369. |
[10] | Wang Lin, Zhang Zinan. Current status and prospects of pulmonary rehabilitation in patients with chronic obstructive pulmonary disease [J]. Journal of Tuberculosis and Lung Disease, 2024, 5(3): 191-196. |
[11] | Zheng Xiaoxia, Zhu Xiaoxiao, Wu Yifan, Gu Fen. The correlation between symptom burden and quality of life in patients with chronic obstructive pulmonary disease [J]. Journal of Tuberculosis and Lung Disease, 2024, 5(3): 207-211. |
[12] | Qiu Qiaojing, Tao Yang, Shen Jiani, Xu Jiapin, Zhu Lihong, Gu Fen. Research of symptom groups of chronic obstructive pulmonary disease and their correlation with patient’s quality of life [J]. Journal of Tuberculosis and Lung Disease, 2024, 5(3): 219-224. |
[13] | Wu Shaozhu, Yu Xueying, Luo Yuanrong, Liu Yanfei, Ke Caixia. The effectiveness of multidisciplinary graded collaborative management on swallowing screening and intervention in patients with chronic obstructive pulmonary disease [J]. Journal of Tuberculosis and Lung Disease, 2024, 5(3): 230-235. |
[14] | Zhang Yidan, Gu Fen, Li Nannan. Current status and nursing research progress of long-term oxygen therapy for patients with chronic obstructive pulmonary disease [J]. Journal of Tuberculosis and Lung Disease, 2024, 5(3): 249-253. |
[15] | Qu Chunjin, Peng Jiayi, Liu Xinyi, Xiao Guanchen, Gu Fen, Li Nannan. Research progress on continuous nursing of patients with chronic obstructive pulmonary disease [J]. Journal of Tuberculosis and Lung Disease, 2024, 5(3): 254-259. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||